Study: NCT01105650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously, 25 mg/m\^2, days -6 through -2 (5 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously, 25 mg/m\^2, days -6 through -2 (5 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously, 25 mg/m\^2, days -6 through -2 (5 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously, 25 mg/m\^2, days -6 through -2 (5 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously, 60 mg/kg, days -5 and -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously, 60 mg/kg, days -5 and -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously, 60 mg/kg, days -5 and -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously, 60 mg/kg, days -5 and -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Administered intravenously, CsA 1.5 mg/kg for target dose range of 150-250 ng/mL day -3 through day +14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Administered intravenously, CsA 1.5 mg/kg for target dose range of 150-250 ng/mL day -3 through day +14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Administered intravenously, CsA 1.5 mg/kg for target dose range of 150-250 ng/mL day -3 through day +14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Administered intravenously, CsA 1.5 mg/kg for target dose range of 150-250 ng/mL day -3 through day +14

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural killer cells
Description: Administered by infusion over less than 1 hour, no more than 8.0 x 10\^7 cells/kg will be given.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural killer cells
Description: Administered by infusion over less than 1 hour, no more than 8.0 x 10\^7 cells/kg will be given.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural killer cells
Description: Administered by infusion over less than 1 hour, no more than 8.0 x 10\^7 cells/kg will be given.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural killer cells
Description: Administered by infusion over less than 1 hour, no more than 8.0 x 10\^7 cells/kg will be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Will be given subcutaneously at 9 million units 3 times a week for a total of 6 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 5 million units/m\^2 3 times per week for 6 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Will be given subcutaneously at 9 million units 3 times a week for a total of 6 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 5 million units/m\^2 3 times per week for 6 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Will be given subcutaneously at 9 million units 3 times a week for a total of 6 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 5 million units/m\^2 3 times per week for 6 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Administered intravenously (IV) 10 mg/kg Days -2 to +4 and 1 mg/kg Days +5 to +9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Administered intravenously (IV) 10 mg/kg Days -2 to +4 and 1 mg/kg Days +5 to +9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Administered intravenously (IV) 1 mg/kg Days -2 to +9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Administered intravenously (IV) 1 mg/kg Days -2 to +9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Will be given subcutaneously at million units 3 times a week for a total of 3 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 3 million units/m\^2 3 times per week for 6 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Will be given subcutaneously at million units 3 times a week for a total of 3 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 3 million units/m\^2 3 times per week for 6 doses).